In terms of philosophy, GE HealthCare’s corporate campus in Chicago is very different from the multinational giant from which it was separated in January 2023. For many years, General Electric was one of the most popular stocks in the United States. Its name was associated with stability and could be found in pension portfolios with AT&T and IBM. The healthcare spinout carried none of that gravitational weight into its independent life, and for the first three years it has been creating something very different: a focused medtech company whose operational performance and stock price have steadfastly refused to follow one another.
On February 4, 2026, the full-year 2025 results were released. The narrative should have pleased investors more than it seemed to. Revenue increased by 4.8% to $20.63 billion. Orders increased naturally by 5.2%. With a book-to-bill ratio of 1.07 times, the business received more orders than it shipped, creating a backlog that management called a record.
The consensus of $1.40 was exceeded by the Q4 adjusted EPS of $1.44. for the earnings call, CEO Peter Arduini focused on the company’s competitive posture, innovation deployment, and momentum in pharmaceutical diagnostics, where organic growth was 12.7 percent for the quarter. These are hardly the figures of a failing company. A different picture is painted by the share price performance.
Important Information
| Field | Details |
|---|---|
| Company | GE HealthCare Technologies Inc. (NASDAQ: GEHC) — spun out of General Electric in January 2023; headquartered in Chicago, Illinois; operations in over 160 countries; approximately 51,000 employees |
| Share Price (April 2026) | Approximately $73–$74, reflecting a 52-week range of roughly $60–$96; market capitalisation approximately $33–34 billion; trailing P/E approximately 16x; forward P/E approximately 14.4x; quarterly dividend $0.035 per share; Goldman Sachs lowered price target from $97 to $81 on April 9, 2026 |
| Full-Year 2025 Results (Feb 4, 2026) | Revenue $20.63 billion (+4.8% reported, +3.5% organic); Q4 revenue $5.70 billion; adjusted EPS Q4 $1.44 (beat consensus of $1.40); net income $2.08 billion; total orders +5.2% organically; book-to-bill ratio 1.07x; record backlog; free cash flow $1.5 billion (impacted by $285 million in tariff costs); adjusted EBIT margin 15.3% vs. 16.3% prior year — entirely explained by tariff drag |
| 2026 Full-Year Guidance | 3–4% organic revenue growth; adjusted EBIT margin 15.8–16.1% (50–80 bps expansion); adjusted EPS $4.95–$5.15; Q1 2026 earnings due April 29, 2026 |
| Key Products / Growth Drivers | Flyrcado (cardiac PET imaging agent, targeting $500M+ revenue by 2028); Allia Moveo AI-supported interventional imaging system (FDA cleared 2025/26); ReadyFix remote fleet management; Vivid Pioneer cardiovascular ultrasound; pharmaceutical diagnostics organic growth +12.7% in Q4 2025 |
| Analyst Consensus | Buy/Outperform consensus from 12–14 analysts; average 12-month price target approximately $88–$93; high target $105 (various), low $77; Mizuho maintained Outperform but lowered target from $95 to $90 on April 13, 2026 citing macro uncertainty |
| Key Risks | Tariff drag (~$100 million per quarter in recent quarters); China market caution (explicit in guidance); margin recovery dependent on Heartbeat operating system efficiency gains; Q1 2026 EPS estimate $1.05 vs prior year $1.44 |
Over the past year, GEHC has trailed the S&P 500 by almost 16%. As of mid-April 2026, it is selling at approximately $73, which is 20% less than what the average Wall Street analyst thinks it should be worth. It is in the middle of a 52-week range that goes from about $60 to $96. Tariffs are part of the explanation, and it’s important to comprehend why this word is so important in discussions with investors. Tariffs cost GE HealthCare over $285 million in free cash flow in 2025. The year’s adjusted EBIT margin was 15.3 percent, down 100 basis points from the previous year’s 16.3 percent.
Management consistently pointed out that margins were higher than the previous year when the tariff impact was taken out of the picture. Despite this, investors continued to concentrate on the tariff line. Flyrcado, an FDA-approved cardiac PET imaging agent currently undergoing commercial deployment, is the product that frequently sparks the most forward-thinking conversation. Flyrcado’s management has set a goal to generate at least $500 million in revenue annually by 2028.
If this goal is achieved, it would make a significant contribution to the pharmaceutical diagnostics market, which is already expanding at a double-digit organic rate. The thesis is simple: Flyrcado uses rubidium-82 to produce faster and more accessible PET scans than older agents, precision cardiac imaging is underutilized worldwide, and GE HealthCare’s existing relationships with hospital systems give it distribution infrastructure that a new entrant could not quickly replicate. One of the more intriguing unanswered questions in the company’s investment case is whether the $500 million aim turns out to be cautious or optimistic.
Observing the price movement during the previous few months, it appears that GEHC is trapped in a holding pattern that could be partially broken by a strong Q1 result on April 29. Due to the tariff impact and the continued downturn of the China market, Q1 expectations remain cautious, with $1.05 EPS compared to $1.44 in the same period last year.
It becomes more difficult to articulate the reasoning behind the stock selling 20% below its consensus goal if the company beats and raises or even just comes in at guidance while displaying margin stabilization. In medtech, this type of pattern—fundamental strength devalued by a macro overhang—has previously been handled. Before earnings quality ultimately prevailed, Medtronic and Stryker both maintained comparable holding patterns for protracted periods of time.
Over the rest of 2026, it’s still uncertain if tariff policy will grow more or less predictable. The most significant factor influencing GEHC’s share price trajectory this year is most likely that uncertainty. The Flyrcado pipeline, the AI-enabled imaging product cycle, and the backlog are all genuine. The tariff bill is genuine as well. Which one investors will be concentrating on on April 29 is the question.
